Literature DB >> 23704210

Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells.

Shidrokh Ardestani1, Bin Li, Desirae L Deskins, Huiyun Wu, Pierre P Massion, Pampee P Young.   

Abstract

TNF-α, produced by most malignant cells, orchestrates the interplay between malignant cells and myeloid cells, which have been linked to tumor growth and metastasis. Although TNF-α can exist as one of two isoforms, a 26-kDa membrane tethered form (mTNF-α) or a soluble 17-kDa cytokine (sTNF-α), the vast majority of published studies have only investigated the biologic effects of the soluble form. We show for the first time that membrane and soluble isoforms have diametrically opposing effects on both tumor growth and myeloid content. Mouse lung and melanoma tumor lines expressing mTNF-α generated small tumors devoid of monocytes versus respective control lines or lines expressing sTNF-α. The lack of myeloid cells was due to a direct effect of mTNF-α on myeloid survival via induction of cell necrosis by increasing reactive oxygen species. Human non-small cell lung carcinoma expressed varying levels of both soluble and membrane TNF-α, and gene expression patterns favoring mTNF-α were predictive of improved lung cancer survival. These data suggest that there are significant differences in the role of different TNF-α isoforms in tumor progression and the bioavailability of each isoform may distinctly regulate tumor progression. This insight is critical for effective intervention in cancer therapy with the available TNF-α inhibitors, which can block both TNF-α isoforms. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23704210      PMCID: PMC3702680          DOI: 10.1158/0008-5472.CAN-13-0002

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.

Authors:  M Kriegler; C Perez; K DeFay; I Albert; S D Lu
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

2.  Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species.

Authors:  S S Deshpande; P Angkeow; J Huang; M Ozaki; K Irani
Journal:  FASEB J       Date:  2000-09       Impact factor: 5.191

3.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

Authors:  Eliza F Chakravarty; Kaleb Michaud; Frederick Wolfe
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

4.  Elevation of cytokine levels in cachectic patients with prostate carcinoma.

Authors:  Jesco Pfitzenmaier; Robert Vessella; Celestia S Higano; Jennifer L Noteboom; David Wallace; Eva Corey
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

5.  Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development.

Authors:  Caroline H Arnott; Kate A Scott; Robert J Moore; Stephen C Robinson; Richard G Thompson; Frances R Balkwill
Journal:  Oncogene       Date:  2004-03-11       Impact factor: 9.867

6.  A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

Authors:  Srinivasan Madhusudan; Martin Foster; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Denis C Talbot; Trivadi S Ganesan; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

7.  Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation.

Authors:  Yong Lin; Swati Choksi; Han-Ming Shen; Qing-Feng Yang; Gang Min Hur; You Sun Kim; Jamie Hong Tran; Sergei A Nedospasov; Zheng-gang Liu
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

8.  Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site.

Authors:  Bin Li; Alicia Vincent; Justin Cates; Dana M Brantley-Sieders; D Brent Polk; Pampee P Young
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes.

Authors:  Abhinav Diwan; Ziad Dibbs; Shintaro Nemoto; Gilberto DeFreitas; Blase A Carabello; Natarajan Sivasubramanian; Eric M Wilson; Francis G Spinale; Douglas L Mann
Journal:  Circulation       Date:  2003-12-29       Impact factor: 29.690

Review 10.  TNF-alpha in promotion and progression of cancer.

Authors:  Frances Balkwill
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

View more
  19 in total

1.  Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma.

Authors:  Xiuru Ma; Xiaoming Li; Xiuying Lu; Lifeng Jia; Hui Li; Qi Song
Journal:  Tumour Biol       Date:  2015-06-27

2.  STAT1 mediates transmembrane TNF-alpha-induced formation of death-inducing signaling complex and apoptotic signaling via TNFR1.

Authors:  Yaping Jiang; Min Yu; Xuena Hu; Lu Han; Kun Yang; Hongping Ba; Zunyue Zhang; Bingjiao Yin; Xiang-Ping Yang; Zhuoya Li; Jing Wang
Journal:  Cell Death Differ       Date:  2017-02-10       Impact factor: 15.828

3.  Assessment of Anti-TNF-α Activities in Keratinocytes Expressing Inducible TNF- α: A Novel Tool for Anti-TNF-α Drug Screening.

Authors:  Sutthirat Udommethaporn; Tewin Tencomnao; Eileen M McGowan; Viroj Boonyaratanakornkit
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

Review 4.  Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment.

Authors:  Yang Qu; Gang Zhao; Hui Li
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

5.  Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.

Authors:  Derek W Edwardson; Justin Boudreau; Jonathan Mapletoft; Carita Lanner; A Thomas Kovala; Amadeo M Parissenti
Journal:  PLoS One       Date:  2017-09-15       Impact factor: 3.240

6.  Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling.

Authors:  Jing Zhang; Yu Yang; Shen'ao Zhou; Xueyan He; Xuan Cao; Chenlu Wu; Hong Hu; Jie Qin; Gang Wei; Huayi Wang; Suling Liu; Liming Sun
Journal:  Cell Death Differ       Date:  2019-10-23       Impact factor: 15.828

Review 7.  Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.

Authors:  Steven F Josephs; Thomas E Ichim; Stephen M Prince; Santosh Kesari; Francesco M Marincola; Anton Rolando Escobedo; Amir Jafri
Journal:  J Transl Med       Date:  2018-08-31       Impact factor: 5.531

8.  Pro-Inflammatory Responses in Human Bronchial Epithelial Cells Induced by Spores and Hyphal Fragments of Common Damp Indoor Molds.

Authors:  Elisabeth Øya; Rune Becher; Leni Ekeren; Anani K J Afanou; Johan Øvrevik; Jørn A Holme
Journal:  Int J Environ Res Public Health       Date:  2019-03-26       Impact factor: 3.390

9.  Membrane TNF-alpha-activated programmed necrosis is mediated by Ceramide-induced reactive oxygen species.

Authors:  Shidrokh Ardestani; Desirae L Deskins; Pampee P Young
Journal:  J Mol Signal       Date:  2013-11-01

10.  Pre-treatment With Ranibizumab Aggravates PDT Injury and Alleviates Inflammatory Response in Choroid-Retinal Endothelial Cells.

Authors:  Yang Liu; Min Zhu; Ruowen Gong; Xin Wang; Lei Li; Gezhi Xu
Journal:  Front Cell Dev Biol       Date:  2020-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.